title: A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan.
abstract: The universal health care system in Japan is facing a historical turning point as a result of the increasing fiscal burden, rapidly aging society, and a decreasing population. To understand the challenges and opportunities in the Japanese pharmaceutical market, which occupies one tenth of the global share, this review highlights several issues related to the benefit-risk assessment that is unique to the modern Japanese society: 1) regulatory system for new drug development; 2) health hazards related to pharmaceuticals ("Yakugai" in Japanese); 3) drug lag; 4) problems and controversies in the vaccination policy; and 5) clinical study misconduct. The regulatory process places a significant importance on Japanese data collection regardless of data accumulation from other countries. Because Yakugai has repeatedly caused tragedies and social disputes historically, the regulatory judgments generally tend to be more prudential when safety concerns are raised for new and emerging pharmaceuticals. Such a regulatory system has caused more than several years of approval delays compared to delays in other countries. The problem of drug lag still lingers on despite several regulatory system revisions, while the solution is incompatible with the elimination of Yakugai because the lag potentially reduces the risk of unpredictable adverse events. The Japanese vaccination policy has also received a lot of criticism, and needs improvements so that the decision-making process can be more transparent and scientifically based. Additionally, repeated clinical study misconduct damaged the reputation of Japanese clinical studies with unnecessary defrayment in health insurance; therefore, the medical community must change its inappropriate relationship with the industry. The problems surrounding pharmaceuticals are related to centralized, strict drug pricing control under the universal health coverage. Although the current government attempts to facilitate innovative research and development of novel therapeutics in Japan, further reforms should be explored for patients who need new and emerging pharmaceuticals.
authors.affiliation: Division of Social Communication System for Advanced Clinical Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Tanimoto
mesh_terms: D000818:Animals; D055808:Drug Discovery / Q000331:legislation & jurisprudence; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007564:Japan; D004364:Pharmaceutical Preparations; D018570:Risk Assessment; D015871:Scientific Misconduct; D014611:Vaccination
chemical_list: D004364:Pharmaceutical Preparations
keywords: MHLW; PMDA; Yakugai; clinical study misconduct; drug lag; vaccination policy
references.citation: N Engl J Med. 2012 Sep 20;367(12):1165-6; author reply 1166-7
references.pmid: 22992090
references.citation: Lancet. 1998 Aug 15;352(9127):554
references.pmid: 9716073
references.citation: Int J Clin Pract. 2011 Nov;65(11):1126-31
references.pmid: 21995691
references.citation: Lancet. 1963 Mar 2;1(7279):501-2
references.pmid: 13961871
references.citation: Lancet. 2011 Jan 22;377(9762):299
references.pmid: 21256381
references.citation: N Engl J Med. 2010 Oct 14;363(16):1578-9; author reply 1579-80
references.pmid: 20942679
references.citation: Science. 2014 Jul 4;345(6192):17
references.pmid: 24994629
references.citation: Lancet. 2012 Apr 14;379(9824):e48
references.pmid: 22500880
references.citation: Lancet. 2013 Sep 14;382(9896):940
references.pmid: 24034298
references.citation: N Engl J Med. 2012 Sep 20;367(12):1082-5
references.pmid: 22970920
references.citation: Health Aff (Millwood). 2013 Apr;32(4):753-61
references.pmid: 23569056
references.citation: Hum Vaccin Immunother. 2014;10(9):2543-50
references.pmid: 25483472
references.citation: Gan To Kagaku Ryoho. 2014 Apr;41(4):410-5
references.pmid: 24743355
references.citation: Ann Intern Med. 2008 Sep 2;149(5):342-9
references.pmid: 18765704
references.citation: Lancet. 2011 Jun 4;377(9781):1919; author reply 1919-20
references.pmid: 21641478
references.citation: Int J Clin Oncol. 2015 Jun;20(3):549-55
references.pmid: 25001869
references.citation: Science. 2013 Jul 19;341(6143):223
references.pmid: 23868992
references.citation: Orphanet J Rare Dis. 2014 Apr 10;9:48
references.pmid: 24716834
references.citation: Nat Med. 1998 Sep;4(9):991
references.pmid: 9734379
references.citation: Eur Heart J. 2013 Apr;34(14):1023
references.pmid: 23376450
references.citation: J Clin Pharm Ther. 2010 Jun;35(3):289-301
references.pmid: 20848767
references.citation: Lancet. 2013 Aug 31;382(9894):768
references.pmid: 23993189
references.citation: Lancet. 2014 Apr 26;383(9927):1460-1461
references.pmid: 24766958
references.citation: Lancet. 2013 Sep 7;382(9895):843
references.pmid: 24012258
references.citation: Lancet. 2012 Feb 11;379(9815):520
references.pmid: 22325660
references.citation: Lancet. 2008 Mar 29;371(9618):1061-2
references.pmid: 18380033
references.citation: Hypertens Res. 2013 Nov;36(11):923
references.pmid: 24048487
references.citation: Gan To Kagaku Ryoho. 2014 Apr;41(4):426-31
references.pmid: 24743358
references.citation: Clin Pharmacol Ther. 2011 Jul;90(1):29-31
references.pmid: 21691273
references.citation: Health Policy. 2012 Oct;107(2-3):312-7
references.pmid: 22727579
references.citation: Clin Pharmacol Ther. 2013 Aug;94(2):195-8
references.pmid: 23872835
references.citation: Intern Med. 2014;53(19):2185-200
references.pmid: 25274229
references.citation: Nature. 2014 Aug 28;512(7515):371
references.pmid: 25164738
references.citation: Nature. 2012 Sep 20;489(7416):346-7
references.pmid: 22996524
references.citation: J Clin Pharm Ther. 2012 Jun;37(3):348-51
references.pmid: 22017294
references.citation: Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17028-33
references.pmid: 23027971
references.citation: J Clin Pharm Ther. 2014 Dec;39(6):649-52
references.pmid: 25200123
references.citation: N Engl J Med. 2004 Feb 5;350(6):552-9
references.pmid: 14762182
references.citation: J Clin Pharmacol. 2015 May;55(5):481-9
references.pmid: 25560978
references.citation: Vaccine. 2014 Jul 23;32(34):4253-8
references.pmid: 24951864
references.citation: J Clin Pharm Ther. 2012 Dec;37(6):657-63
references.pmid: 22734557
references.citation: Lancet. 2014 Jun 21;383(9935):2111
references.pmid: 24959638
references.citation: Clin Pharmacol Ther. 2014 May;95(5):467-9
references.pmid: 24747231
references.citation: Neuropathology. 2000 Sep;20 Suppl:S20-4
references.pmid: 11037182
references.citation: Lancet. 1995 Sep 9;346(8976):701-2
references.pmid: 7658837
references.citation: Invest New Drugs. 2013 Apr;31(2):473-8
references.pmid: 22965890
references.citation: Lancet. 2015 Jun 6;385(9984):2297-307
references.pmid: 25576992
references.citation: Nature. 2014 Sep 18;513(7518):287-8
references.pmid: 25230622
references.citation: Clin Pharmacol Ther. 2010 Feb;87(2):212-8
references.pmid: 19940847
references.citation: Pharm Pract (Granada). 2006 Oct;4(4):168-78
references.pmid: 25214906
references.citation: Ann Pharmacother. 2010 Dec;44(12):1976-85
references.pmid: 21098757
references.citation: Lancet. 2007 Dec 15;370(9604):2063-7
references.pmid: 18083405
references.citation: Health Policy. 2012 Mar;104(3):241-6
references.pmid: 22172246
references.citation: Lancet. 2011 Sep 24;378(9797):1174-82
references.pmid: 21885098
references.citation: N Engl J Med. 2010 May 13;362(19):1832-9
references.pmid: 20463344
references.citation: Lancet. 2012 Nov 10;380(9854):1647
references.pmid: 23141615
references.citation: Lancet. 2014 Sep 20;384(9948):1098
references.pmid: 25241720
references.citation: Invest New Drugs. 2011 Aug;29(4):706-12
references.pmid: 21286780
references.citation: Oncologist. 2008 Sep;13(9):993-1000
references.pmid: 18784156
references.citation: N Engl J Med. 2012 Jun 14;366(24):2284-93
references.pmid: 22591257
references.citation: Nat Rev Drug Discov. 2015 Jan;14(1):1-2
references.pmid: 25503331
references.citation: N Engl J Med. 2006 Dec 28;355(26):2787; author reply 2787-8
references.pmid: 17193722
references.citation: Lancet. 2011 Oct 1;378(9798):1265-73
references.pmid: 21885100
references.citation: Nature. 2013 May 30;497(7451):548
references.pmid: 23719442
references.citation: Blood. 2013 May 30;121(22):4439-42
references.pmid: 23620577
references.citation: Intern Med. 2011;50(15):1565-8
references.pmid: 21804282